Evidence map›Paper›PMID 27075636›Full record

ArticleLeukemia & lymphoma2016

Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.

Sarah A Milgrom, Chan Y Cheah, Chelsea C Pinnix, Grace L Smith, Bouthaina S Dabaja, Patricia Horace, Patricia Chevez-Barrios, Nathan H Fowler, Dan S Gombos

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sarah A Milgroma Department of Radiation Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Chan Y Cheahb Department of Medical Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Chelsea C Pinnixa Department of Radiation Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Grace L Smitha Department of Radiation Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Bouthaina S Dabajaa Department of Radiation Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Patricia Horacea Department of Radiation Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Patricia Chevez-Barriosc Department of Pathology , MD Anderson Cancer Center , Houston , TX , USA ;
Nathan H Fowlerb Department of Medical Oncology , MD Anderson Cancer Center , Houston , TX , USA ;
Dan S Gombosd Department of Ophthalmology , MD Anderson Cancer Center , Houston , TX , USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Economic Strain and Resilience in Cancer Patients: Assessing Patient-Reported Measures of the Burdens of TreatmentK07CA211804 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SMITH, GRACE · 2016 to 2020
$853k
NCI NIH HHS K07 CA211804
6 · The paper itself

Abstract

Primary intraocular lymphoma (PIOL) is a rare malignancy with poor outcomes. Concerns regarding toxicity lead some clinicians to exclude orbital radiation therapy (RT). We aimed to quantify the ocular toxicity of RT in 11 PIOL patients treated with chemoimmunotherapy and bilateral orbital RT (median 36 Gy). A multidisciplinary team, including an ocular oncologist, followed patients for a median of 42 months after RT. Common adverse events included dermatitis (100%), conjunctivitis (82%), xerophthalmia (64%), and keratopathy (45%). All phakic eyes developed cataracts (100%); correction resulted in good vision recovery. New, visually significant retinopathy was observed in only one eye (<5%) and affected a patient with preexisting diabetes. This report suggests that severe, vision-threatening complications following orbital RT are uncommon. In the absence of comorbidities, orbital RT should not be withheld due to fear of vision-threatening toxicity. The risk of toxicity may be augmented by comorbidities, so an individualized approach is recommended.

Indexed as

AgedBiomarkersBiopsyCombined Modality TherapyDisease ManagementEye DiseasesFemaleFollow-Up StudiesHumansImmunohistochemistryIntraocular LymphomaMaleMiddle AgedMultimodal ImagingRadiation InjuriesRadiotherapyBiomarkersOrbitalPIOLprimary intraocular lymphomaradiation therapyradiotherapyRT

Identifiers

PMID27075636
PMCPMC6047351
OpenAlexW2340423434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.